April 30, 2019 Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424
April 16, 2019 Cerevance Appoints Industry Veteran Roland Bürli, Ph.D. as Vice President of Drug Discovery
March 5, 2019 Industry Central Nervous System Specialist Lee Dawson, Ph.D. Joins Cerevance as VP of Neuroscience
September 25, 2018 Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of Parkinson’s Disease
November 27, 2017 Cerevance Appoints David H. Margolin, M.D., Ph.D., as Senior Vice President of Clinical and Translational Medicine
October 24, 2017 Trailblazer in Molecular Genetics and Neuroscience, Jeremy Nathans, M.D., Ph.D., to Advise Cerevance
October 17, 2017 Cerevance Licenses Human Brain Tissue Profiling Technology from The Rockefeller University
October 12, 2017 Harvard’s Rudolph Tanzi, Ph.D., a Leader in Alzheimer’s Disease Genetics, Joins Cerevance’s Advisory Board
